Precision medicine and the antiphospholipid syndrome: what is the future?

Clin Rheumatol. 2020 Apr;39(4):1015-1017. doi: 10.1007/s10067-020-04987-8. Epub 2020 Feb 15.

Authors

Ignasi Rodriguez-Pintó¹, Gerard Espinosa², Ricard Cervera³

Affiliations

¹ Autoimmune Diseases Unit, Hospital Universitari Mútua de Terrassa, Terrassa, Catalonia, Spain.
² Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Villarroel 170, 08036, Barcelona, Catalonia, Spain.
³ Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Villarroel 170, 08036, Barcelona, Catalonia, Spain. rcervera@clinic.cat.

PMID: 32060811
DOI: 10.1007/s10067-020-04987-8

No abstract available

Publication types

Editorial

MeSH terms

Abortion, Spontaneous / immunology
Abortion, Spontaneous / prevention & control*
Antibodies, Anticardiolipin / immunology
Antibodies, Antiphospholipid / immunology*
Anticoagulants / therapeutic use*
Antiphospholipid Syndrome / drug therapy*
Antiphospholipid Syndrome / immunology
Aspirin / therapeutic use
Heparin / therapeutic use
Humans
Immunoglobulin G / immunology
Immunoglobulin M / immunology
Lupus Coagulation Inhibitor / immunology
Patient Selection
Phosphatidylserines / immunology
Platelet Aggregation Inhibitors / therapeutic use*
Precision Medicine*
Premature Birth / immunology
Premature Birth / prevention & control*
Prothrombin / immunology
Risk Assessment
Thrombosis / prevention & control*
beta 2-Glycoprotein I / immunology

Substances

Antibodies, Anticardiolipin
Antibodies, Antiphospholipid
Anticoagulants
Immunoglobulin G
Immunoglobulin M
Lupus Coagulation Inhibitor
Phosphatidylserines
Platelet Aggregation Inhibitors
beta 2-Glycoprotein I
Prothrombin
Heparin
Aspirin